Phasebio Pharmaceuticals (PHAS) Receives a Buy from Stifel Nicolaus

Stifel Nicolaus analyst Derek Archila reiterated a Buy rating on Phasebio Pharmaceuticals (PHASResearch Report) yesterday. The company’s shares closed last Monday at $3.71.

According to TipRanks.com, Archila is a 4-star analyst with an average return of 7.3% and a 43.2% success rate. Archila covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Madrigal Pharmaceuticals, and Apellis Pharmaceuticals.

Phasebio Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $16.50.

See today’s analyst top recommended stocks >>

Phasebio Pharmaceuticals’ market cap is currently $179.8M and has a P/E ratio of -1.00. The company has a Price to Book ratio of 20.92.

Based on the recent corporate insider activity of 21 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of PHAS in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

PhaseBio Pharmaceuticals, Inc. is engaged in the development and commercialization of biotherapeutics for the treatment of orphan diseases. It focuses on cardiopulmonary disorders. The company was founded by Ashutosh Chilkoti and Clay Bernardin Thorp in January 2002 and is headquartered in Malvern, PA.